OptimizeRx (OPRX) Stock Price, News & Analysis

Company Overview

OptimizeRx, Inc. is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations. These tools allow pharmaceutical and biotechnology firms to deliver personalized messaging to physicians and care teams, ensuring that relevant formulary and financial support information is accessible at the moment of treatment. In addition, OptimizeRx provides data analytics and reporting capabilities that enable clients to measure the impact of their digital outreach and refine strategies to drive prescription growth and patient outcomes.

Founded in 2003 and headquartered in Cleveland, Ohio, OptimizeRx has formed partnerships with a broad spectrum of EHR vendors and health systems across the United States. The company’s network reaches tens of thousands of healthcare providers, making it one of the largest point-of-care communication platforms in the country. OptimizeRx collaborates closely with payers to integrate eligibility and benefit information, ensuring that savings offers and coverage details are accurate and up to date.

OptimizeRx is led by Chief Executive Officer David Whitlinger, who joined the company in 2019 and has overseen its expansion of digital service offerings and strategic alliances. Under his leadership, the company has focused on enhancing interoperability, scaling its network footprint and delivering advanced analytics to clients. While its primary market remains the U.S., OptimizeRx continues to explore opportunities to extend its digital health network into new regions and therapeutic areas.

Key Stats

• Today's Range: $17.85 to $19.00
• 50-Day Range: $12.48 to $18.92
• 52-Week Range: $3.78 to $19.25
• Volume: 363,974 shs
• Average Volume: 341,889 shs
• Market Capitalization: $351.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.81
• Consensus Rating: Moderate Buy

OptimizeRx Stock Analysis - MarketRank™

OptimizeRx scored higher than 26% of companies evaluated by MarketBeat, and ranked 555th out of 663 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

OptimizeRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.

Downside Risk

OptimizeRx has a consensus price target of $11.81, representing about 37.6% downside from its current price of $18.92.

Amount of Analyst Coverage

OptimizeRx has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for OptimizeRx are expected to grow in the coming year, from ($0.33) to ($0.29) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of OptimizeRx is -35.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of OptimizeRx is -35.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

OptimizeRx has a P/B Ratio of 2.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.06% of the float of OptimizeRx has been sold short.

Short Interest Ratio / Days to Cover

OptimizeRx has a short interest ratio ("days to cover") of 4.3.

Change versus previous month

Short interest in OptimizeRx has recently increased by 11.57%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OptimizeRx does not currently pay a dividend.

Dividend Growth

OptimizeRx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.06% of the float of OptimizeRx has been sold short.

Short Interest Ratio / Days to Cover

OptimizeRx has a short interest ratio ("days to cover") of 4.3.

Change versus previous month

Short interest in OptimizeRx has recently increased by 11.57%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.56

News Sentiment

OptimizeRx has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Computer and Technology companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for OptimizeRx this week, compared to 3 articles on an average week.

Search Interest

Only 14 people have searched for OPRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

4 people have added OptimizeRx to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, OptimizeRx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $194,489.00 in company stock.

Percentage Held by Insiders

Only 5.60% of the stock of OptimizeRx is held by insiders.

Percentage Held by Institutions

76.47% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OPRX Stock Analysis - Frequently Asked Questions

How have OPRX shares performed this year?

OptimizeRx's stock was trading at $4.86 at the start of the year. Since then, OPRX shares have increased by 289.3% and is now trading at $18.92.

How were OptimizeRx's earnings last quarter?

OptimizeRx Corp. (NASDAQ:OPRX) posted its earnings results on Monday, May, 12th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.19. The company had revenue of $21.93 million for the quarter, compared to analysts' expectations of $18.69 million. OptimizeRx had a positive trailing twelve-month return on equity of 4.50% and a negative net margin of 9.42%.
Read the conference call transcript.

Who are OptimizeRx's major shareholders?

OptimizeRx's top institutional shareholders include Blair William & Co. IL (3.40%), Kennedy Capital Management LLC (2.54%), Manatuck Hill Partners LLC (2.45%) and Geode Capital Management LLC (2.16%). Insiders that own company stock include William J Febbo, James Paul Lang, Patrick D Spangler and Marion Odence-Ford.
View institutional ownership trends.

How do I buy shares of OptimizeRx?

Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of OptimizeRx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OptimizeRx investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 9/18/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Computer and Technology
• Industry: COMP - SOFTWARE
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:OPRX
• CIK: 1448431
• Web: www.optimizerx.com
• Phone: (248) 651-6568
• Fax: 248-453-5529
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Price Target for OptimizeRx: $11.81
• High Price Target: $20.00
• Low Price Target: $5.00
• Potential Upside/Downside: -37.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.66 million
• Net Margins: -9.42%
• Pretax Margin: -8.88%
• Return on Equity: 4.50%
• Return on Assets: 3.12%

Debt

• Debt-to-Equity Ratio: 0.21
• Current Ratio: 2.57
• Quick Ratio: 2.57

Sales & Book Value

• Annual Sales: $92.13 million
• Price / Sales: 3.81
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.35 per share
• Price / Book: 2.98

Miscellaneous

• Outstanding Shares: 18,570,000
• Free Float: 17,525,000
• Market Cap: $351.34 million
• Optionable: Optionable
• Beta: 1.20